These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12883372)

  • 1. Virus therapy of human cancers.
    Sinkovics JG; Horvath JC
    Melanoma Res; 2003 Aug; 13(4):431-2. PubMed ID: 12883372
    [No Abstract]   [Full Text] [Related]  

  • 2. Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.
    Ascierto PA; Mozzillo N; Caracò C; Parasole R; Palmieri G; Melucci MT; Botti G; Castello G
    Ann Oncol; 2000 Nov; 11(11):1504. PubMed ID: 11142495
    [No Abstract]   [Full Text] [Related]  

  • 3. Does adjuvant vaccine therapy really have activity in malignant melanoma?
    Wheatley K; Ives NJ; Lorigan P
    J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa.
    Mitchell MS; Darrah D; Stevenson L
    Cancer Invest; 2002; 20(5-6):759-68. PubMed ID: 12197233
    [No Abstract]   [Full Text] [Related]  

  • 5. Current state of treatment for primary cutaneous melanoma.
    Chung ES; Sabel MS; Sondak VK
    Clin Exp Med; 2004 Oct; 4(2):65-77. PubMed ID: 15672943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon adjuvant therapy of melanoma.
    Kirkwood JM; Wazer D; Rosenstein M
    Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of adjuvant therapy in cutaneous melanoma.
    Sondak VK
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):421-6. PubMed ID: 12113108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of adjuvant interferon study in WHO melanoma programme.
    Cascinelli N; Bufalino R; Morabito A; Mackie R
    Lancet; 1994 Apr; 343(8902):913-4. PubMed ID: 7908370
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of basal cell carcinoma with intralesional interferon.
    Vinciullo C
    Australas J Dermatol; 1993; 34(1):36. PubMed ID: 8240187
    [No Abstract]   [Full Text] [Related]  

  • 10. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).
    Csatary LK; Moss RW; Beuth J; Töröcsik B; Szeberenyi J; Bakacs T
    Anticancer Res; 1999; 19(1B):635-8. PubMed ID: 10216468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate.
    Cassel WA; Murray DR
    Nat Immun Cell Growth Regul; 1988; 7(5-6):351-2. PubMed ID: 3065642
    [No Abstract]   [Full Text] [Related]  

  • 12. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory reaction presages response in melanoma skin lesions during i.m. rIFN alpha-2a-based treatment.
    Bracarda S; Roila F; Basurto C; Tonato M
    Ann Oncol; 1990 Sep; 1(5):381. PubMed ID: 2148107
    [No Abstract]   [Full Text] [Related]  

  • 14. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
    Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
    Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine therapy for malignant melanoma.
    Morton DL; Barth A
    CA Cancer J Clin; 1996; 46(4):225-44. PubMed ID: 8673695
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
    Hanson DS; Leggette CT
    Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
    [No Abstract]   [Full Text] [Related]  

  • 18. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of melanoma: an update.
    Homsi J; Grimm JC; Hwu P
    Surg Oncol Clin N Am; 2011 Jan; 20(1):145-63. PubMed ID: 21111964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontiers in adjuvant therapy in stage II-III melanoma.
    Eggermont AM
    Tumori; 2001; 87(4):S60-3. PubMed ID: 11693827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.